- Home
- PBBK vs BOLD Comparison
PBBK vs BOLD Comparison
Compare PBBK & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBBK
- BOLD
- Stock Information
- Founded
- PBBK 1919
- BOLD 2018
- Country
- PBBK United States
- BOLD United States
- Employees
- PBBK N/A
- BOLD 64
- Industry
- PBBK Banks
- BOLD
- Sector
- PBBK Finance
- BOLD
- Exchange
- PBBK Nasdaq
- BOLD Nasdaq
- Market Cap
- PBBK 37.3M
- BOLD 33.4M
- IPO Year
- PBBK N/A
- BOLD 2024
- Fundamental
- Price
- PBBK $15.65
- BOLD $1.65
- Analyst Decision
- PBBK
- BOLD Hold
- Analyst Count
- PBBK 0
- BOLD 1
- Target Price
- PBBK N/A
- BOLD N/A
- AVG Volume (30 Days)
- PBBK 4.6K
- BOLD 57.4K
- Earning Date
- PBBK 04-23-2025
- BOLD 05-09-2025
- Dividend Yield
- PBBK N/A
- BOLD N/A
- EPS Growth
- PBBK 12.26
- BOLD N/A
- EPS
- PBBK 0.83
- BOLD N/A
- Revenue
- PBBK $12,804,000.00
- BOLD N/A
- Revenue This Year
- PBBK N/A
- BOLD N/A
- Revenue Next Year
- PBBK N/A
- BOLD N/A
- P/E Ratio
- PBBK $18.78
- BOLD N/A
- Revenue Growth
- PBBK 5.21
- BOLD N/A
- 52 Week Low
- PBBK $12.70
- BOLD $1.06
- 52 Week High
- PBBK $17.75
- BOLD $12.26
- Technical
- Relative Strength Index (RSI)
- PBBK 50.31
- BOLD N/A
- Support Level
- PBBK $15.48
- BOLD N/A
- Resistance Level
- PBBK $15.70
- BOLD N/A
- Average True Range (ATR)
- PBBK 0.09
- BOLD 0.00
- MACD
- PBBK -0.00
- BOLD 0.00
- Stochastic Oscillator
- PBBK 43.60
- BOLD 0.00
About PBBK PB Bankshares Inc.
PB Bankshares Inc follows a community bank model and provides multiple services to individuals and small to midsize businesses. Its business consists of attracting retail and commercial deposits from the general public in its market area and investing those deposits, together with funds generated from operations and borrowings, in commercial real estate loans, commercial and industrial loans, construction, home equity lines of credit and to a lesser extent, one- to four-family residential real estate loans and consumer loans.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.